Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG - Related Studies

Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG

This study has been completed.

Study NCT00037713. Last updated on October 29, 2008. Information provided by ImClone Systems

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Carcinoma, Small Cell Lung

2	Additional conditions recognized in this trial
		Carcinoma
		Carcinoma, Small Cell
		Lung Neoplasms

3	More general conditions related to this trial
		Adenocarcinoma
		Carcinoma, Neuroendocrine
		Lung Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Germ Cell and Embryonal
		Neoplasms, Glandular and Epithelial
		Neoplasms, Nerve Tissue
		Neuroectodermal Tumors
		Neuroendocrine Tumors
		Respiratory Tract Diseases
		Respiratory Tract Neoplasms
		Thoracic Neoplasms

4	Interventions listed in this trial
		BEC2 Vaccine

5	Sponsors listed in this trial
		ImClone Systems
		Merck KGaA
		EORTC Lung Cancer Cooperative Group
		Spanish Lung Cancer Group
		Schweizerische Arbeitsgruppe fuer angewandte Krebsforschung (SAKK)
		Centers of Veterans' Administration
		Groupe Francais De Pneumo-Cancerologie
		Memorial Sloan-Kettering Cancer Center
		Independent centers (Australia, New Zealand, Europe, USA)